Ramorelix

Summary

Ramorelix is a synthetic peptide GnRH antagonist developed in the 1990s. It was investigated primarily for the treatment of hormone-sensitive conditions such as prostate cancer and benign prostatic hyperplasia (BPH), as well as for endometriosis and assisted reproduction. Unlike GnRH agonists, it causes immediate suppression of gonadotropins without a testosterone flare. Development was discontinued and it never reached regulatory approval.

Mechanism of Action

Competitive antagonist of gonadotropin-releasing hormone (GnRH) receptors in the anterior pituitary, leading to rapid suppression of LH and FSH release without an initial flare effect, resulting in decreased gonadal steroid production.

Routes of Administration

Goals & Uses

• Assisted reproduction / controlled ovarian stimulationReproductive MedicineLow
• Benign prostatic hyperplasia (BPH)UrologyLow
• Prostate cancer treatmentOncologyLow
• EndometriosisGynecologyLow

Contraindications

• Known hypersensitivity to GnRH analogsAllergyHigh
• PregnancyPopulationHighPotential fetal risk or insufficient safety data

Adverse Effects

• Injection site reactionsLocalCommon
• Histamine release / allergic reactionImmunologicUncommon
• Hypogonadism symptomsEndocrineCommon
• Bone mineral density reductionMusculoskeletalUncommon

Drug Interactions

• QT-prolonging agentsModerate

Population Constraints

• Pediatric patientsAgeRelative
• Patients with cardiovascular diseaseComorbidityRelative

Regulatory Status

• European UnionUnapprovedNever received EMA approval; clinical trials conducted in Europe in the 1990s but not progressed.
• United StatesUnapprovedNever submitted for or received FDA approval; development discontinued.
• United KingdomUnapprovedNo regulatory approval in the UK.

Ramorelix was never approved by any major regulatory authority. Clinical development was halted; it remains a research-stage compound with no approved indications.

Evidence & Sources

No sources recorded yet.